Cycurion, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Cycurion reported Q3 2026 revenue of $5.4M (up 40% YoY from $3.8M), beating consensus of $4.37M, with gross profit surging to $1.9M (36% margin vs. 7% prior year). Operating loss narrowed 35% to $3.0M; Adjusted EBITDA loss improved 64% to $1.2M. Growth driven by acquisitions (Secuvant in June 2026, Cycurion Digital Ally on Aug 3, 2026, contributing ~$1.2M) and modest organic growth ($0.3M). Company faces going-concern warning, working capital deficit of $10.5M (vs. $8.9M year-end 2025), and net debt of $5.3M. Cash position: $3.0M (down from $5.3M year-end). Warrant inducement raised $4.5M gross proceeds mid-quarter. 10-year state health/human services contract ($54.6M total value over 10 years) expected to commence Q1 2027.
Why this rating
Revenue and margin improvement real but modest vs. $10.1M market cap; acquisition-driven growth masks flat organic base; going-concern risk and $10.5M working capital deficit material threats to runway; no near-term path to cash flow breakeven disclosed.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.